Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is an observational study in which data already collected from people with venous thromboembolism (VTE) due to sepsis (blood poisoning) are studied. These people were hospitalized in an intensive care unit (ICU) and may or may not have had disseminated intravascular coagulation (DIC).
In this observational study, only observations are made without participants receiving any advice or changes to their healthcare.
VTE is a condition that occurs when blood clots form in the veins, which can be dangerous. DIC is a serious blood disorder that can cause clots throughout the body, blocking blood flow. People who have sepsis are at a higher risk of developing both VTE and DIC. Researchers wanted to know if people who have sepsis developed DIC before developing VTE.
To prevent VTE in people with sepsis, it is important to know how severe the sepsis is, how it progresses, and whether DIC is also present or not.
In this study, researchers will assess patient data from a medical database in the United States (US).
The main purpose of this study is to learn if there is a relationship between sepsis, DIC, and VTE.
To do this, researchers will divide the participants with VTE due to sepsis into three groups as follows:
The researchers will collect the following information:
The researchers will study the data collected between January 2007 and December 2021.
The data will come from the participants' information stored in a database called the Optum VTE EHR which collects patient medical data from hospitals across the US.
In this study, only available data from routine care are collected. No visits or tests are required as part of this study.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Diagnosed DIC | Patients with ICD10 (International Classification of Diseases) code for DIC |
| |
| Undiagnosed DIC | Patients with SIC (Sepsis Induced Coagulopathy) score of >/= 4 |
| |
| No DIC | Patients with no DIC within the same hospital stay |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Diagnosis of both VTE and sepsis | Other | Both diagnoses need to present during ICU stay for case inclusion into this retrospective study |
|
| Measure | Description | Time Frame |
|---|---|---|
| Prevalence of diagnosed DIC among hospitalized people with sepsis-associated VTE | Retrospective analysis of 15 year dataset | |
| Proportion of undiagnosed DIC among hospitalized people with sepsis-associated VTE | Based on trajectory of laboratory and vital sign data from the time of sepsis ICD10 coding to the time of VTE coding and to the time of DIC coding | Retrospective analysis of 15 year dataset |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
All inpatients admitted to an ICU with the diagnosis of VTE and sepsis during the same hospital ICU admission, within the Optum VTE EHR dataset from 1 January 2007 to 31 December 2021
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Bayer | Whippany | New Jersey | 07981 | United States |
Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D018805 | Sepsis |
| D054556 | Venous Thromboembolism |
| D004211 | Disseminated Intravascular Coagulation |
| ID | Term |
|---|---|
| D007239 | Infections |
| D018746 | Systemic Inflammatory Response Syndrome |
| D007249 | Inflammation |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D013923 | Thromboembolism |
| D016769 | Embolism and Thrombosis |
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
| D001778 | Blood Coagulation Disorders |
| D006402 | Hematologic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
| D006474 | Hemorrhagic Disorders |
| D019851 | Thrombophilia |
Not provided
Not provided